Source: The Hindu Business Line, Feb 18, 2019
New Delhi: There is a speculation that prices of certain drugs may go up, considering that costs of Active Pharmaceutical Ingredients (API) that India imports from China have increased compared to last year.
“This comes in the light of re-opening of revamped Chinese facilities that had shut shop last year, due to regulatory issues,” said Karthikeyan Thangaranjan, Associate Director, India Ratings and Research Pvt Ltd.
Costs of certain APIs, which are the core ingredients that go into formulation of drugs, had doubled over the last year, as over a lakh Chinese facilities closed. “Prices of APIs and key starting materials originating from China have started to moderate but are likely to settle at higher-than-the-previous-average levels. We are speculating a 20-30 per cent rise in costs of certain APIs that India imports from China,” Thangarajan told BusinessLine. Read the rest of this entry »